Physician

Ronak Chandrakant Shah, M.D.

According to 2025 Medicare claims, Ronak Shah, M.D. (NPI: 1033145800) practices nephrology in the Modesto, CA market, with the plurality of this provider's patient population coming from Stanislaus, CA. This provider's primary affiliated billing organization is SUTTER VALLEY MEDICAL FOUNDATION (NPI: 1669846986; TIN: 680273974) and primary practice location at 95355-4201. Shah is affiliated with the Sutter Medicare Direct (ACO ID: A5279), participating under the MSSP model.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 756 traditional Medicare patients, billed 7,658 HCPCS/CPT codes, and received $440,718 in Medicare payments. The top billing code was 90962 (Dialysis services, 1 physician visit per month (20 years or older)). Part D data shows 3,970 prescription claims across 591 beneficiaries totaling $485,479 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 126 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $925,674 to $485,479. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $941 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	842	5,369	$460,917
2016	800	5,393	$473,824
2017	789	5,510	$497,455
2018	792	5,784	$470,714
2019	819	7,082	$517,780
2020	787	5,946	$479,835
2021	783	5,126	$455,030
2022	758	5,158	$453,746
2023	732	5,279	$441,076
2024	756	7,658	$440,718

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	421	5,867	$925,674
2016	411	5,146	$903,235
2017	410	4,246	$829,502
2018	388	3,942	$477,907
2019	416	3,756	$455,735
2020	414	3,732	$497,019
2021	408	3,862	$460,979
2022	507	4,026	$661,146
2023	487	3,639	$640,312
2024	591	3,970	$485,479

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	285	$14,596
2016	37	340	$14,561
2017	25	214	$7,892
2018	N/R	132	$4,428
2019	12	227	$13,946
2020	N/R	236	$12,358
2021	N/R	168	$7,088
2022	N/R	110	$4,750
2023	N/R	129	$3,299
2024	N/R	126	$1,668

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90962	Dialysis services, 1 physician visit per month (20 years or older)	94	374	$161
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	186	223	$135
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	310	602	$92
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	309	1,378	$62
90935	Hemodialysis procedure with physician evaluation	122	365	$55

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	38	1,260	$108,339
Farxiga	Dapagliflozin Propanediol	96	3,400	$62,459
Xphozah	Tenapanor Hcl	12	360	$34,965
Veltassa	Patiromer Calcium Sorbitex	33	973	$32,757
Prosol	Parenteral Amino Acid 20% No.1	164	1,117	$27,716

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	36	$630
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	25	$428
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	29	$389
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	20	$209
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	N	N/R	16	$12

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Ronak Chandrakant Shah, M.D.?

Tedicare shows public-source Medicare data for Ronak Chandrakant Shah, M.D. (NPI 1033145800), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ronak Chandrakant Shah, M.D. have ACO affiliation data?

Ronak Chandrakant Shah, M.D. is shown with ACO affiliation data for Sutter Medicare Direct (MSSP, ACO ID A5279).

What billing organization is linked to Ronak Chandrakant Shah, M.D.?

Ronak Chandrakant Shah, M.D. is linked to SUTTER VALLEY MEDICAL FOUNDATION (billing NPI 1669846986) in the available physician profile data.

Does Ronak Chandrakant Shah, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.